ArticleMedical science monitor : international medical journal of experimental and clinical research2018
Upregulation of CXCR7 Is Associated with Poor Prognosis of Prostate Cancer.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- G protein-coupled receptors in prostate cancer: research progress and therapeutic targets.Frontiers in cell and developmental biology · 2025Review
- SubvertingBiology · 2024Review
- Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.The Journal of clinical investigation · 2023Article
- CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells.Oncogene · 2022Article
- Review
- Review
- Effects of SDF-1/CXCR7 on the Migration, Invasion and Epithelial-Mesenchymal Transition of Gastric Cancer Cells.Frontiers in genetics · 2021Article
- CXCR7: a β-arrestin-biased receptor that potentiates cell migration and recruits β-arrestin2 exclusively through Gβγ subunits and GRK2.Cell & bioscience · 2020Article
- Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression.Oncology reports · 2020Observational
- Article
- Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Prostate cancer (PCa) is a prevalent cancer in males. CXCR7 exhibits oncogenic actions in various cancers. The aim of our study was to explore the clinical significance of CXCR7 in patients with PCa. MATERIAL AND METHODS QRT-PCR was used to detect the expression level of CXCR7 in PCa tissues. The relationship between CXCR7 expression and clinicopathologic parameters was evaluated by chi-square test. Kaplan-Meier survival curve was used for the survival analysis of patients. Cox regression analyses were performed to assess the potential of CXCR7 as a prognosis biomarker for PCa patients. We performed MTT and Transwell assays to determine the effect of CXCR7 on proliferative and migratory abilities of PCa cells, respectively. RESULTS CXCR7 was upregulated in PCa tissues (P<0.05) and was correlated with PSA (P=0.023), differentiation (P=0.022), and lymph node metastasis (P=0.018). The results of MTT and Transwell assays demonstrated that inhibition of CXCR7 suppressed PCa cells growth and migration. Additionally, high CXCR7 level predicted poor overall survival (log rank test, P=0.019). CXCR7 was a valuable prognostic biomarker for PCa patients (HR=2.271, 95%CI=1.093-4.719, P=0.028). CONCLUSIONS CXCR7 is an oncogene in PCa that can promote aggressive progression of PCa through enhancing proliferation and migration of the tumor cells. CXCR7 is an independent biomarker for the prognosis of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.